Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C A Nationwide Survey in Taiwan

• Published in: Medicine (Baltimore) Vol. 94; no. 13; p. e690
• Main Authors: Yu, Ming-Lung, Yeh, Ming-Lun, Tsai, Pei-Chien, Huang, Ching-I., Huang, Jee-Fu, Huang, Chung-Feng, Hsieh, Meng-Hsuan, Liang, Po-Cheng, Lin, Yi-Hung, Hsieh, Ming-Yen, Lin, Wen-Yi, Hou, Nai-Jen, Lin, Zu-Yau, Chen, Shinn-Cherng, Dai, Chia-Yen, Chuang, Wan-Long, Chang, Wen-Yu
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health 01.04.2015
• Subjects: Adult; Aged; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - epidemiology; Hepatitis C, Chronic - therapy; Humans; Interferon-alpha - administration & dosage; Interferon-alpha - adverse effects; Interferon-alpha - therapeutic use; Male; Medication Adherence; Middle Aged; Observational Study; Polyethylene Glycols - administration & dosage; Polyethylene Glycols - adverse effects; Polyethylene Glycols - therapeutic use; Prevalence; Prospective Studies; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Recombinant Proteins - therapeutic use; Ribavirin - administration & dosage; Ribavirin - adverse effects; Ribavirin - therapeutic use; Taiwan - epidemiology

Peginterferon/ribavirin provides a substantially high treatment efficacy for chronic hepatitis C virus (HCV) infections in Asians. Whether the clinical efficacy can be translated to community effectiveness remains unclear. The disease awareness, treatment accessibility, recommendations, acceptance,...